⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNA News
Avidity Biosciences, Inc. Common Stock
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
prnewswire.com
RNA
Form 8-K
sec.gov
RNAM
RNA
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
globenewswire.com
NVS
RNA
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
globenewswire.com
NVS
RNA
Form 8-K
sec.gov
RNA
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
prnewswire.com
RNA
Form 8-K
sec.gov
RNA
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
prnewswire.com
RNA
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
prnewswire.com
RNA
Avidity Biosciences Announces Expected Record Date for Spin-Off
prnewswire.com
RNA